



Children's National®

Minutes

IBC Meeting

Date: October 15, 2025

Time: 4PM

Location: Zoom Meeting – Meeting ID 978 0700 9250

Call-in number: 301-715-8592

Attendees: Jermaine Lawson, Sydney Villanueva, James Novak, Daniel Bobb, Stephanie Gomez, Lumen Chao, Beata Jablonska, Kenta Umetsu, Kerry Belton, Kenneth Dolan

Members Absent: Cristiano Escano, Michael Keller

Guests: Alavy Sos

Agenda Topic	Discussion Lead	Notes	Time
Call to Order	Jermaine Lawson	The meeting was called to order when quorum was fulfilled. Attendance was documented by the administrator.	4:12PM
Meeting Minutes	Jermaine Lawson	The minutes for the 08/13/2025 meeting were approved. <u>Vote</u> Approve = 6	4:12PM

Minutes



		Oppose = 0 Abstain = 0 Defer = 0	
Announcements	Jermaine Lawson	<ul style="list-style-type: none">Jermaine Lawson gave a regulatory update regarding the NIH Guidelines.	4:13PM
Protocol Review	Jermaine Lawson	<p>Protocol Amendment: 10013-IBC-Keller</p> <p>Principal Investigator – Michael Keller</p> <p>Protocol Title – Developing combined innate/adaptive immune-based therapies against cancer and opportunistic infections for immune-compromised patients</p> <p><u>Committee Action</u></p> <p>Full committee review of protocol 10013, which was amended to add adenovirus.</p> <p><u>Project Summary</u></p> <p>The project summary was presented by Jermaine Lawson followed by protocol discussion by the committee.</p>	4:23PM

Minutes



Children's National®

		<p style="text-align: center;"><u>Remarks</u></p> <p>The committee identified the following issues to be addressed by project PI after review and discussion of the submitted project.</p> <ul style="list-style-type: none">• There is no mention of the adenovirus experiments in section 3B. PI should add a brief description of how AAV will be used.• For biohazard box 5, question 8, the PI should specify where the AAV work is to take place.• In biohazard box 5, question 1, the PI should specify which subtypes of live adenovirus will be used, if applicable. <p style="text-align: center;"><u>Vote</u></p> <p>The committee voted to approve the protocol.</p> <p style="text-align: center;">Approve = 10 Oppose = 0 Abstain = 0 Defer = 0</p>	
Meeting Activity	Stephanie Gomez	Stephanie Gomez excused herself from the meeting for a potential conflict of interest regarding the next protocol.	4:28PM

Minutes



Children's National®

Protocol Review	Jermaine Lawson	<p>New Protocol Submission: 25-10073-IBC-Meany Project PI – Holly Meany Protocol Title – Selective Antigen Specific dTβRII-expressing T cells and B7-H3 CAR T cells in subjects with Relapsed/refractory Embryonal tumors (SABRE)</p> <p><u>Committee Action</u> Full committee review of protocol 25-10073, which was a new submission for the use of retrovirus, human derived materials, and staphylococcal enterotoxin B.</p> <p><u>Project Summary</u> The project summary was presented by Jermaine Lawson followed by protocol discussion by the committee.</p> <p><u>Remarks</u> The committee identified the following issues to be addressed by project PI after review and discussion of the submitted project.</p> <ul style="list-style-type: none">• SEB is indicated as not being inactivated before being disposed of as biohazardous	4:29PM
-----------------	-----------------	--	--------

Minutes



Children's National®

		<p>waste. This waste should be bleached prior to disposal.</p> <ul style="list-style-type: none">• Post approval monitoring is required for this protocol. This will be performed by the BSO on an annual basis to ensure biosafety compliance. <p style="text-align: center;"><u>Vote</u></p> <p>The committee voted to approve the protocol.</p> <p style="text-align: center;">Approve = 9 Oppose = 0 Abstain = 0 Defer = 0</p>	
Adjournment	Jermaine Lawson	The meeting was adjourned at 4:40PM.	4:40PM